Promoter methylation correlates with reduced SMAD4 expression in patients with breast cancer
Abstract Purpose Over the past decades, there is a dramatic rise in the mortality and incidence rates of breast cancer globally, despite the progressive advancement of therapeutic options. Late detection of breast cancer is often the main culprit for the ineffective treatment, and death in patients....
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-08-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02966-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849332273628839936 |
|---|---|
| author | Archana Chaudhary Manish Kumar Lalit Mohan Rizwanul Haque Pankaj Prabhakar Mohammad Shamsul Ola Md. Margoob Ahmad |
| author_facet | Archana Chaudhary Manish Kumar Lalit Mohan Rizwanul Haque Pankaj Prabhakar Mohammad Shamsul Ola Md. Margoob Ahmad |
| author_sort | Archana Chaudhary |
| collection | DOAJ |
| description | Abstract Purpose Over the past decades, there is a dramatic rise in the mortality and incidence rates of breast cancer globally, despite the progressive advancement of therapeutic options. Late detection of breast cancer is often the main culprit for the ineffective treatment, and death in patients. Finding breast cancer biomarkers is thus of significant importance. Epigenetic modifications are associated with up and down regulation of important biomarker in the TGF-β pathway, such as SMAD4, which may have a greater impact in the growth and poor prognosis in breast cancer. In the current investigation we are going to check how SMAD4 regulate in various Breast cancer patients? And how its epigenetic modifications play crucial role in disease prognosis? Methods Twenty eight samples of patients with proven breast cancer and the adjacent normal tissue from the same patients were analyzed for SMAD4 expression using real-time PCR and Western blot. Additionally, MS-PCR was employed to detect the epigenetic and genetic alterations. Result SMAD4 expression dropped from Grade 1 to Grade 3 breast cancer both at mRNA and protein level as justified by real time PCR as well as western blot. This down regulation of SMAD4 expression is due to its promoter methylation, which may be a major contributing reason to the dysregulated production of SMAD4 in instances of breast cancer. Conclusion According to these findings, SMAD4 status assessment in breast cancer, fine-needle biopsy specimens may offer further prognostic data. Worse prognosis was linked to reduced SMAD4 expression due to promoter methylation in Breast cancer. |
| format | Article |
| id | doaj-art-d91e52b217e54cf4a093a2bb7c4d913d |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-d91e52b217e54cf4a093a2bb7c4d913d2025-08-20T03:46:15ZengSpringerDiscover Oncology2730-60112025-08-0116111110.1007/s12672-025-02966-6Promoter methylation correlates with reduced SMAD4 expression in patients with breast cancerArchana Chaudhary0Manish Kumar1Lalit Mohan2Rizwanul Haque3Pankaj Prabhakar4Mohammad Shamsul Ola5Md. Margoob Ahmad6Department of Pharmacology, Indira Gandhi Institute of Medical SciencesDepartment of Surgical Oncology, Indira Gandhi Institute of Medical SciencesDepartment of Pharmacology, Indira Gandhi Institute of Medical SciencesDepartment of Biotechnology, Central University of South BiharDepartment of Pharmacology, Indira Gandhi Institute of Medical SciencesDepartment of Biochemistry, College of Science, King Saud UniversityDepartment of Pharmacology, Indira Gandhi Institute of Medical SciencesAbstract Purpose Over the past decades, there is a dramatic rise in the mortality and incidence rates of breast cancer globally, despite the progressive advancement of therapeutic options. Late detection of breast cancer is often the main culprit for the ineffective treatment, and death in patients. Finding breast cancer biomarkers is thus of significant importance. Epigenetic modifications are associated with up and down regulation of important biomarker in the TGF-β pathway, such as SMAD4, which may have a greater impact in the growth and poor prognosis in breast cancer. In the current investigation we are going to check how SMAD4 regulate in various Breast cancer patients? And how its epigenetic modifications play crucial role in disease prognosis? Methods Twenty eight samples of patients with proven breast cancer and the adjacent normal tissue from the same patients were analyzed for SMAD4 expression using real-time PCR and Western blot. Additionally, MS-PCR was employed to detect the epigenetic and genetic alterations. Result SMAD4 expression dropped from Grade 1 to Grade 3 breast cancer both at mRNA and protein level as justified by real time PCR as well as western blot. This down regulation of SMAD4 expression is due to its promoter methylation, which may be a major contributing reason to the dysregulated production of SMAD4 in instances of breast cancer. Conclusion According to these findings, SMAD4 status assessment in breast cancer, fine-needle biopsy specimens may offer further prognostic data. Worse prognosis was linked to reduced SMAD4 expression due to promoter methylation in Breast cancer.https://doi.org/10.1007/s12672-025-02966-6BC (Breast Cancer)SMAD4TGF-βCancer biomarker |
| spellingShingle | Archana Chaudhary Manish Kumar Lalit Mohan Rizwanul Haque Pankaj Prabhakar Mohammad Shamsul Ola Md. Margoob Ahmad Promoter methylation correlates with reduced SMAD4 expression in patients with breast cancer Discover Oncology BC (Breast Cancer) SMAD4 TGF-β Cancer biomarker |
| title | Promoter methylation correlates with reduced SMAD4 expression in patients with breast cancer |
| title_full | Promoter methylation correlates with reduced SMAD4 expression in patients with breast cancer |
| title_fullStr | Promoter methylation correlates with reduced SMAD4 expression in patients with breast cancer |
| title_full_unstemmed | Promoter methylation correlates with reduced SMAD4 expression in patients with breast cancer |
| title_short | Promoter methylation correlates with reduced SMAD4 expression in patients with breast cancer |
| title_sort | promoter methylation correlates with reduced smad4 expression in patients with breast cancer |
| topic | BC (Breast Cancer) SMAD4 TGF-β Cancer biomarker |
| url | https://doi.org/10.1007/s12672-025-02966-6 |
| work_keys_str_mv | AT archanachaudhary promotermethylationcorrelateswithreducedsmad4expressioninpatientswithbreastcancer AT manishkumar promotermethylationcorrelateswithreducedsmad4expressioninpatientswithbreastcancer AT lalitmohan promotermethylationcorrelateswithreducedsmad4expressioninpatientswithbreastcancer AT rizwanulhaque promotermethylationcorrelateswithreducedsmad4expressioninpatientswithbreastcancer AT pankajprabhakar promotermethylationcorrelateswithreducedsmad4expressioninpatientswithbreastcancer AT mohammadshamsulola promotermethylationcorrelateswithreducedsmad4expressioninpatientswithbreastcancer AT mdmargoobahmad promotermethylationcorrelateswithreducedsmad4expressioninpatientswithbreastcancer |